<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The coagulation <z:e sem="disease" ids="C0584960" disease_type="Disease or Syndrome" abbrv="">factor V Leiden mutation</z:e>, leading to resistance to activated protein C (APC), is the most common inherited risk factor for <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In various systemic <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> the <z:e sem="disease" ids="C0398623" disease_type="Disease or Syndrome" abbrv="">hypercoagulable state</z:e> was shown to be associated with the presence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) </plain></SENT>
<SENT sid="2" pm="."><plain>Our aim was to determine the prevalence of both, Leiden mutation and aPL in <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> and their impact on the occurrence of <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The dataset consists of results from 137 patients having <z:e sem="disease" ids="C1527336" disease_type="Disease or Syndrome" abbrv="">Sj√∂gren's syndrome</z:e> (n = 50), progressive systemic <z:mp ids='MP_0000612'>sclerosis</z:mp> (n = 43) (<z:chebi fb="17" ids="53277">PSS</z:chebi>), <z:e sem="disease" ids="C0409999" disease_type="Disease or Syndrome" abbrv="">undifferentiated connective tissue disease</z:e> (n = 24) (UCTD) and <z:e sem="disease" ids="C0026272" disease_type="Disease or Syndrome" abbrv="MCTD">mixed connective tissue disease</z:e> (n = 20) (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCTD</z:e>) with or without venous thromboembolic complications </plain></SENT>
<SENT sid="4" pm="."><plain>The Leiden mutation was detected with polymerase chain reaction (PCR), aPL, such as <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LA) with screening and confirmatory procedures and others with enzyme linked immunosorbent assay (ELISA) </plain></SENT>
<SENT sid="5" pm="."><plain>The prevalence of mutation ranged between 8.3% and 18.0% (13.1%) </plain></SENT>
<SENT sid="6" pm="."><plain>The thromboembolic risk was found to be increased in the presence of aPL </plain></SENT>
<SENT sid="7" pm="."><plain>Eight patients (5.84%) (4 heterozygous) experienced <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> and 3 out of 4 heterozygous showed aPL positivity, too </plain></SENT>
<SENT sid="8" pm="."><plain>There were no difference between the frequencies of Leiden mutation in examined systemic <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> and unselected populations </plain></SENT>
</text></document>